Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2023
Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapyYi Bao, Yuanyuan Qiao, Jae Eun Choi, et al.
Cell Reports. Medicine|March 25, 2026
Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumorsYizhi Cao, Caleb Cheng, Yitong Yin, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 17, 2023
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory responseYuanyuan Qiao, Jesse W Wotring, Yang Zheng, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancerCaleb Cheng, Jing Hu, Rahul Mannan, et al.
Biorxiv : the Preprint Server for Biology|July 30, 2026
A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate CancerYang Zheng, Caleb Cheng, Yizhi Cao, et al.
Cancer Research Communications|July 17, 2026
Development and Validation of a Multimodal-Multitask Deep Learning Approach for Estimating Late Distant Recurrence Risk in HR-Positive Early Breast CancerEleftherios P Mamounas, Ming Chen, Joseph A Sparano, et al.
Cancer Cell|August 3, 2026
A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancerYang Zheng, Caleb Cheng, Yizhi Cao, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Caleb Cheng, Yuanyuan Qiao, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 2024
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Caleb Cheng, Yuanyuan Qiao, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2025
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinomaJean Ching-Yi Tien, Yali Zhai, Rong Wu, et al.
Pageof 14